Bayer reorganizes its businesses; NantKwest fills out exec ranks;

@FierceBiotech: Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask. More | Follow @FierceBiotech

@JohnCFierce: The British papers seem particularly outraged by Shkreli. Feeling a bit sorry/outraged for the Yanks? Understandable. | Follow @JohnCFierce

@DamianFierce: "Industry analysts often cite the day Taiwanese animators got involved as the peak of the biotech bubble." Watch | Follow @DamianFierce

> Starting next year, Bayer will divide its business between pharmaceuticals, consumer health and crop science, a move the company said will better integrate its global divisions. News

> Patrick Soon-Shiong's NantKwest ($NK) is filling out its upper ranks after a record-setting IPO, recruiting a new executive medical director, senior vice president of medical affairs and senior vice president mergers and acquisitions. More

> Ampio Pharmaceuticals ($AMPE) is moving forward with a second Phase III trial on its treatment for osteoarthritis pain after the FDA signed off on a special protocol assessment. Item

Medical Device News

@FierceMedDev: Sequenom appoints new CEO amid diversification. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: CMS proposal to restrict coverage of artificial limbs facing pushback from amputees. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Clorox reveals smartphone-powered UV cleaning device for drug-resistant bacteria. Article | Follow @EmilyWFierce

> Biogen VP Karaboutis rallies company for med tech R&D push. More

> NIH gives med tech company $1.9M to improve deep brain stimulation for Parkinson's. Story

Pharma News

@FiercePharma: China's WuXi NextCODE builds on Fudan University partnership with Children's Hospital pact. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Novo to build a $78M insulin pen plant in Iran. FiercePharmaManufacturing news | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: New ulcerative colitis data could help Pfizer's Xeljanz pick up the pace. Article | Follow @CarlyHFierce

> Valeant's latest tax-cutting tactic, courtesy of Luxembourg. Report

> J&J faces Tylenol lobbying allegations in first case to go to trial over med. Story

> Rough waters for pharma's U.S. pricing power, yes. Sea change? Nope. Article

Drug Delivery News

> Drug-carrying nanoparticles disguised as platelets could help heal blood vessels. Report

> BDSI touts fed's plan to remove barriers on medication-assisted treatment of drug addiction. More

> West Pharma adds medication adherence tracking capability to its drug delivery system. Item

> Silicone vaginal ring could deliver HIV, herpes drugs at low cost. Story

> Impel NeuroPharma bags $4M to develop its device to deliver drugs across blood-brain barrier. Article

Pharma Manufacturing News

> Huge Russian plasma products plant moving forward. Article

> Novo to build $78M plant in Iran. News

> China's ShangPharma to build biologics plant in Qidong. Story

> GSK sets up network to help its suppliers cut emissions. Item

> McKesson nails down another international supply chain deal. Report

Pharma Asia News

> Serum Institute pushes for dengue cure fast track, Times of India says. Article

> WuXi NextCODE bolsters Fudan University alliance with Children's Hospital pact. News

> Novartis CEO says company to make heart failure drug Entresto at Singapore plant. Item

> Shanghai-based ZAI Lab in-licenses autoimmune candidate from UCB. Story

> China's BGI and Huawei partner on Big Data genomic system storage. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.